Endo International has been developing a non-surgical treatment cellulite for a number of years. Tuesday the company announced the FDA agreed to review its Biologics License Application for collagenase clostridium histolyticum (CCH) for the treatment of cellulite. FDA approval and a commercial launch of its novel cellulite treatment is one step closer to realilty.
In February experts discussed Endo International, Xiaflex and Cellulite. The discussion was led by Senator Maria Chappelle-Nadal, Ralph Baker of Shocking The Street and Torian Mitchell (COO of AYCE Network). They parsed the potential for Xiaflex to treat cellulite. Endo is expected to file an application with the FDA for Xiaflex to be indicated to treat cellulite. The findings of the panel could help shape that application.
Cellulite affects women and men. Xiaflex will be targeted to women, so what they think about the product will likely drive market potential and ultimate pricing.